NYSEARCA:PEKCRRD VanEck Vectors ChinaAMC CSI 300 ETF (PEKCRRD) Price, Holdings, & News → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free PEKCRRD Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AAssets Under Management$27.76 millionDividend YieldN/ANet Expense Ratio0.00% Stock AnalysisStock Analysis Get VanEck Vectors ChinaAMC CSI 300 ETF alerts: Email Address About VanEck Vectors ChinaAMC CSI 300 ETFRead More Ad Behind the MarketsThe Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>> PEKCRRD ETF News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive PEKCRRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VanEck Vectors ChinaAMC CSI 300 ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details Issuer Fund NameVanEck Vectors ChinaAMC CSI 300 ETF Tax Classification Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:PEKCRRD Inception Date1/1/2100 Fund ManagerN/A WebN/A PhoneN/AFund Focus Asset Class BenchmarkN/A Category Focus Development Level Region Number of Holdings0 Fund Statistics Assets Under Management$27.76 million Average Daily Volume$0.00 Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorN/A AdvisorN/A CustodianN/A DistributorN/A Transfer AgentN/A TrusteeN/A Lead Market MakerN/A Miscellaneous Outstanding SharesN/ABetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Ad Behind the MarketsThe Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>> VanEck Vectors ChinaAMC CSI 300 ETF ExpensesTypePEKCRRDNYSEARCA ETFsAll ETFsManagement Fee0.00%0.51%0.51%Other Expenses0.00%0.64%0.58%Total Expense0.00%0.74%0.70%Fee Waiver0.00%-0.68%-0.57%Net Expense0.00%0.58%0.58% VanEck Vectors ChinaAMC CSI 300 ETF (PEKCRRD)Full Holdings Details Similar ETFsFranklin FTSE Europe Hedged ETFNYSEARCA:FLEHiShares iBonds Mar 2023 Term Corporate ex-Financials ETFNYSEARCA:IBCEBlack Creek Diversified Property FundNYSEARCA:ZDPFTXJPMorgan ActiveBuilders U.S. Large Cap Equity ETFNYSEARCA:JUSAGlobal X MSCI Pakistan ETFNYSEARCA:PAK PEKCRRD ETF - Frequently Asked Questions How do I buy shares of VanEck Vectors ChinaAMC CSI 300 ETF? Shares of PEKCRRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEARCA:PEKCRRD) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityGold Set to EXPLODE!Gold Safe ExchangeThe AI Stock that’s Disrupting Every IndustryStockEarningsShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Vectors ChinaAMC CSI 300 ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
